Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verrilli, M. R.
Right arrow Articles by Bennetts, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verrilli, M. R.
Right arrow Articles by Bennetts, M.
NEUROLOGY 1987;37:865
© 1987 American Academy of Neurology

Phenelzine toxicity responsive to dantrolene

Michael R. Verrilli, MS, DO, Virgilio D. Salanga, MS, MD, Walter E. Kozachuk, MD and Michael Bennetts, MD

Departments of Internal Medicine (Dr. Verrilli), Neurology (Drs. Salanga and Kozachuk), and Psychiatry (Dr. Bennetts), The Cleveland Clinic Foundation. Cleveland, OH.

We describe a 44-year-old man with signs of phenelzine sulfate (a monoamine oxidase inhibitor) toxicity, including coma, hyperpyrexia, hypotension, tachycardia, generalized muscular rigidity, and hyperreflexia. He recovered after IV treatment with dantrolene. Dantrolene appears to be an effective treatment for phenelzine toxicity manifested by a hypermetabolic state.

Address correspondence and reprint requests to Dr. Salangs, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH 44106.

Received May 19, 1986. Accepted for publication in final form August 27, 1986.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.